Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis

• Market Cap: ₹5.85B
• Dividend Yield: N/A
• Average Volume (3M): 2.19K
• Price to Earnings (P/E): 20.0
• Beta (1Y): 1.02
• Revenue Growth: 32.95%
• EPS Growth: 67.39%
• Country: IN
• Employees: 168
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.97
• Shares Outstanding: 17,480,782
• 10 Day Avg. Volume: 2,304
• 30 Day Avg. Volume: 2,185
• PEG Ratio: 0.27
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 2.92
• P/FCF Ratio: -19.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹372.00 ▲(4.61% Upside)

Kilitch Drugs' overall stock score is driven by its strong financial performance, despite challenges in operational efficiency and cash flow management. Technical indicators suggest bearish momentum, which weighs on the score. The valuation is moderate, but the lack of a dividend yield reduces its appeal to certain investors.

Positive Factors

Revenue Growth

The company's robust revenue growth indicates expanding market reach and effective product adoption, supporting long-term business sustainability.

Market Diversification

International market expansion diversifies revenue streams and reduces dependency on domestic sales, enhancing resilience against local market fluctuations.

Product Innovation

Continuous investment in R&D fosters innovation, allowing Kilitch to stay competitive and meet evolving market demands, driving future growth.

Negative Factors

Operational Efficiency

Challenges in operational efficiency can hinder profit maximization, affecting long-term profitability and competitiveness.

Cash Flow Management

Negative free cash flow growth indicates potential liquidity issues, which could limit the company's ability to invest in growth opportunities.

EBIT and EBITDA Margins

Suboptimal EBIT and EBITDA margins reflect inefficiencies that could impact profitability, necessitating strategic improvements for sustained growth.

Kilitch Drugs (India) Limited Business Overview & Revenue Model

Company Description

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

How the Company Makes Money

Kilitch Drugs generates revenue primarily through the sale of its pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has diversified its revenue streams by engaging in contract manufacturing for other pharmaceutical firms, which allows it to leverage its production capabilities. Additionally, Kilitch explores international markets, exporting its products to various countries, which contributes significantly to its earnings. Strategic partnerships with healthcare providers and other pharmaceutical companies enhance its market presence and drive sales. The company's focus on research and development also enables it to innovate and introduce new products, further bolstering its revenue potential.

Kilitch Drugs (India) Limited Financial Statement Overview

Summary

Kilitch Drugs shows strong revenue growth and improved profit margins, indicating robust financial health. However, operational efficiency and cash flow management need improvement, as evidenced by moderate EBIT and EBITDA margins and challenges in converting profits into positive cash flow.

Income Statement

Kilitch Drugs has demonstrated robust revenue growth with a notable increase in total revenue from previous years. The gross profit margin is healthy, indicating effective cost management. Net profit margin has improved significantly, showcasing enhanced profitability. However, the EBIT and EBITDA margins, although positive, suggest room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet reflects a strong equity position with a favorable equity ratio. The debt-to-equity ratio is moderate, suggesting a balanced approach to leverage. Return on Equity (ROE) indicates a positive return on shareholder investments, although it could be further optimized. Overall, the balance sheet is stable but has potential for better utilization of assets.

Cash Flow

The cash flow statement shows challenges in free cash flow, with negative growth in recent periods due to increased capital expenditures. The operating cash flow to net income ratio is positive but indicates that the company is facing difficulties in translating earnings into cash flow. Improvements in cash management could enhance financial flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.08B	1.98B	1.54B	1.40B	1.14B	681.28M
Gross Profit	1.00B	937.39M	731.38M	624.64M	337.44M	300.07M
EBITDA	442.15M	426.26M	287.43M	206.50M	134.13M	79.85M
Net Income	280.03M	267.01M	146.01M	104.48M	73.67M	36.71M
Balance Sheet
Total Assets	0.00	3.13B	2.40B	2.20B	2.10B	2.03B
Cash, Cash Equivalents and Short-Term Investments	593.65M	593.98M	690.19M	591.77M	572.43M	488.49M
Total Debt	0.00	494.24M	316.46M	221.94M	204.32M	148.04M
Total Liabilities	-2.00B	1.12B	643.88M	689.41M	695.55M	736.97M
Stockholders Equity	2.00B	2.02B	1.76B	1.52B	1.39B	1.27B
Cash Flow
Free Cash Flow	0.00	-293.31M	-65.97M	-12.26M	-24.19M	93.61M
Operating Cash Flow	0.00	175.42M	-1.46M	25.86M	57.83M	456.59M
Investing Cash Flow	0.00	-399.47M	-95.45M	79.15M	-152.50M	-375.69M
Financing Cash Flow	0.00	132.43M	88.07M	-7.16M	70.28M	16.14M

Kilitch Drugs (India) Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 355.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Negative. The current price of 355.6 is above the 20-day moving average (MA) of 344.13, above the 50-day MA of 352.46, and below the 200-day MA of 385.25, indicating a bearish trend. The MACD of -1.25 indicates Positive momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 9.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KILITCH.

Kilitch Drugs (India) Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹9.72B	13.81	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.40B	2.57	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.34B	43.00	―	―	24.20%	55.01%
KILITCH	57 Neutral	₹5.85B	19.95	―	―	32.95%	67.39%
MEDICAMEQ	57 Neutral	₹5.29B	47.58	―	0.26%	-9.16%	49.09%
NECLIFE	52 Neutral	₹4.09B	-1.13	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kilitch Drugs (India) Limited Corporate Events

Kilitch Drugs Submits Quarterly Monitoring Report

Kilitch Drugs (India) Limited has submitted its Monitoring Agency Report for the quarter ending September 30, 2025, in compliance with SEBI regulations. This report, prepared by Infomerics Valuation and Rating Limited, reflects the company’s adherence to regulatory requirements and will be available on the company’s website, indicating transparency and accountability to stakeholders.